Appendix 3: List of excluded studies and reasons for exclusion

Study ID	Reference	Reason for exclusion
Al-Hihi 2017	Al-Hihi E, Badgett RG. In moderate-to-severe sciatica, pregabalin did not reduce leg pain intensity or improve quality of life. Annals of internal medicine. 2017; (2):[Jc4 p.]. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/558/CN-01394558/frame.html.	Not primary report of RCT
Anon 2010	Anonymous. Pregabalin effective in relieving post-traumatic peripheral neuropathic pain. Australian Journal of Pharmacy. 2010;91 (1086):82.	Not primary report of RCT
Baron 2008	Baron R, Brunnmuller U, Brasser M, May M, Binder A. Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study. European Journal of Pain. 2008;12(7):850-8.	Open label; also no placebo control
Baron 2010	Baron R, Freynhagen R, Tolle TR, Cloutier C, Leon T, Murphy TK, et al. The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. Pain. 2010;150 (3):420-7.	Randomization based on response to interventions in run-in phase
Boyle 2012	Boyle J, Eriksson MEV, Gribble L, Gouni R, Johnsen S, Coppini DV, et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: Impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes care. 2012;35 (12):2451-8.	No placebo control; only placebo run in

Calkins 2014	Calkins A, Shurman J, Jaros M, Kim R, Shang G. Peripheral edema and weight gain in adult patients with painful diabetic peripheral neuropathy (DPN) receiving gabapentin enacarbil (GEN) or pregabalin enrolled in a randomized phase 2 trial. Neurology Conference: 66th American Academy of Neurology Annual Meeting, AAN. 2014;82(10 SUPPL. 1).	Did not report neuropathic pain as an outcome
Cardenas 2012	Cardenas D, Nieshoff E, Suda K, Goto S, Kaneko T, Parsons B, et al. A 17-week, randomized, double-blind, placebo-controlled, parallel-group, multi-center trial of pregabalin for the treatment of chronic central neuropathic pain after spinal cord injury. Journal of pain. 2012;Conference: 31st Annual Scientific Meeting of the American Pain Society. Honolulu, HI United States. Conference Publication: (var.pagings). 13 (4 SUPPL. 1):S62.	Duplicate of study already included in the review: Duplicate of Cardenas 2013
Cardenas 2013	Cardenas DD, Nieshoff E, Parsons B, Sanin L, Kaneko T, Suzuki M, et al. Assessment of neuropathic pain during a 17-week, double-blind, placebo-controlled, trial of pregabalin in patients with spinal cord injury. Regional Anesthesia and Pain Medicine Conference: 11th Annual ASRA Pain Medicine Meeting Miami, FL United States Conference Publication:. 2013;38(1).	Duplicate of study already included in the review: Duplicate of Cardenas 2013
De Andrade 2015	De Andrade DC, Teixeira MJ, Galhardoni R, Ferreira KASL, Malieno PB, Scisci N, et al. A phase III, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of pregabalin in the prevention and reduction of oxaliplatin-induced painful neuropathy (PreOx). Journal of Clinical Oncology Conference. 2015;33(15 SUPPL. 1).	Pain experienced during cancer chemotherapy

Duarte 2014	Duarte MAG, Cardenas-Soto K, Lem M, Castillo C, Gibbons C, Freeman R. Efficacy of pregabalin in the treatment of prediabetic neuropathic pain. Neurology Conference: 66th American Academy of Neurology Annual Meeting, AAN. 2014;82(10 SUPPL. 1).	No placebo control; evaluation in open-label run-in
Eerdekens 2016	Eerdekens M, Koch ED, Kok M, Sohns M, Forst T. Cebranopadol, a novel first-inclass analgesic: Efficacy, safety, tolerability in patients with pain due to diabetic peripheral neuropathy (U). Pain practice. 2016;Conference: 8th World Congress of the World Institute of Pain, WIP 2016. New York City, NY United States. Conference Publication: (var.pagings). 16 (SUPPL. 1):100.	Unclear how many participants were in each intervention arm
Freynhagen 2006	Freynhagen R, Busche P, Konrad C, Balkenohl M. [Effectiveness and time to onset of pregabalin in patients with neuropathic pain]. Der Schmerz. 2006;20(4):285-8.	Non-English study: Duplicate of Freynhagen 2005
Gabrani 2016	Gabrani A, Dobi D, Tomori S, Berberi F, Como A, Kapisyzi MR. Efectiveness of pregabalin compared with amytriptilin in acute Herpetic Neuralgia. Neurology Conference: 68th American Academy of Neurology Annual Meeting, AAN. 2016;86(16 SUPPL. 1).	Not a placebo-controlled study
Gilron 2011	Gilron I, Wajsbrot D, Therrien F, Lemay J. Pregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo-controlled trial. Clinical journal of pain. 2011;27(3):185-93.	Single-blinded Randomization to placebo/PGB occurred after a run in period of pre-gabalin?
Gonzalez-Duarte 2016	Gonzalez-Duarte A, Lem M, Diaz-Diaz E, Castillo C, Cardenas-Soto K. The Efficacy of Pregabalin in the Treatment of Prediabetic Neuropathic Pain. Clinical journal of pain. 2016;32(11):927-32.	Randomization based on response to interventions in run-in phase

Jenkins 2010	Jenkins T, Smart T, Hackman F, Cooke C, Tan K, Cheung R. Pregabalin in post-traumatic peripheral neuropathic pain: Efficient assessment of efficacy in a randomised, double-blind, placebo-controlled crossover study. European Journal of Pain Supplements. 2010;Conference: 3rd International Congress on Neuropathic Pain. Athens Greece. Conference Publication: (var.pagings). 4 (1):89.	Duplicate of study already excluded from the review: Jenkins 2012
Jenkins 2012	Jenkins TM, Smart TS, Hackman F, Cooke C, Tan KKC. Efficient assessment of efficacy in post-traumatic peripheral neuropathic pain patients: Pregabalin in a randomized, placebo-controlled, crossover study. Journal of pain research. 2012;5:243-50.	Phase I: proof of concept
Jensen-Dahm 2011	Jensen-Dahm C, Rowbotham MC, Reda H, Petersen KL. Effect of a single dose of pregabalin on herpes zoster pain. Trials [Electronic Resource]. 2011;12(55):28.	Phase 2
Kruszewski 2007	Kruszewski SP, Shane JA. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology. 2007;68(24):2158-9.	Not primary report of RCT
Mishra 2012	Mishra S, Bhatnagar S, Goyal GN, Rana SPS, Upadhya SP. A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. American Journal of Hospice & Palliative Medicine. 2012;29(3):177-82.	Pain experienced during cancer chemotherapy

Morrison 2015	Morrison S, Parson H, Vinik AI. Pregabalin positively affects subjective pain, falls risk, and gait in persons with diabetic peripheral neuropathy. Diabetes. 2015;Conference: 75th Scientific Sessions of the American Diabetes Association. Boston, MA United States. Conference Publication: (var.pagings). 64 (SUPPL. 1):A164.	Cross-over trial that did not report data from first phase
Parsons 2013	Parsons B, Emir B. Examining the time-to-improvement of pain in patients with chronic neuropathic pain due to spinal cord injury. Journal of pain. 2013;Conference: 32nd Annual Scientific Meeting of the American Pain Society. New Orleans, LA United States. Conference Publication: (var.pagings). 14 (4 SUPPL. 1):S60.	Not primary report of RCT: report of 2 separate primary studies included in review
Parsons 2015	Parsons B, Emir B, Knapp L. Examining the Time to Improvement of Sleep Interference With Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy and Postherpetic Neuralgia. American journal of therapeutics. 2015;22(4):257-68.	Not primary report of RCT
Parsons 2012	Parsons B, Nieshoff E, Cardenas D, Sanin L, Kaneko T, Suzuki M, et al. Weekly assessments of pain and sleep during a 17-week, double-blind, placebo-controlled trial of pregabalin for the treatment of chronic neuropathic pain after spinal cord injury. Neurology. 2012;Conference: 64th American Academy of Neurology Annual Meeting. New Orleans, LA United States. Conference Publication: (var.pagings). 79 (11):e88.	Duplicate of study already included in the review: Duplicate of Cardenas 2013

Parsons 2015 (Ann Neur)	Parsons B, Shang N, Yan P, Fan D. Efficacy and safety of pregabalin for postherpetic neuralgia in Chinese patients. Annals of Neurology. 2015;Conference: 140th Annual Meeting of the American Neurological Association, ANA 2015. Chicago, IL United States. Conference Publication: (var.pagings). 78 (SUPPL. 19):S92.	Duplicate of study already included in the review: Duplicate of Liu 2015
Puiu 2015	Puiu T, Kairys A, Pauer L, Schmidt-Wilcke T, Ichesco E, Hampson J, et al. Alterations in brain gray matter volume are associated with reduced evoked-pain connectivity following acute pregabalin administration. Neurology Conference: 67th American Academy of Neurology Annual Meeting, AAN. 2015;84(SUPPL. 14).	Included participants with fibromyalgia
Raskin 2014	Raskin P, Huffman C, Toth C, Asmus MJ, Messig M, Sanchez RJ, et al. Pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy: a randomized withdrawal trial. Clinical journal of pain. 2014;30(5):379-90.	Randomization based on response to interventions in run-in phase
Satoh 2011	Satoh J, Yagihashi S, Baba M, Suzuki M, Arakawa A, Yoshiyama T. Efficacy and safety evaluation of pregabalin treatment over 52weeks in patients with diabetic neuropathic pain extended after a double-blind placebo-controlled trial. Journal of diabetes investigation. 2011;2 (6):457-63.	Open label; also no placebo control

van Seventer 2009	Van Seventer R, Murphy K, Temple J, McKenzie I, Serpell M, Toth C, et al. Pregabalin is effective in the treatment of posttraumatic peripheral neuropathic pain. Journal of pain. 2009;Conference: 28th Annual Scientific Meeting of the American Pain Society, APS. San Diego, CA United States. Conference Publication: (var.pagings). 10 (4 SUPPL. 1):S35.	Duplicate of study already included in the review: Van Seventer 2010
Vinik 2014- 1	Vinik A, Rosenstock J, Sharma U, Feins K, Hsu C, Merante D. Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes care. 2014;37 (12):3253-61.	Proof of concept study
Vinik 2014-2	Vinik A, Sharma U, Feins K, Hsu C, Merante D. Central nervous system safety and tolerability of DS-5565: A randomized, double-blind, placebo-and active comparator-controlled phase II study in diabetic peripheral neuropathic pain. Neurology Conference: 66th American Academy of Neurology Annual Meeting, AAN. 2014;82(10 SUPPL. 1).	Duplicate of study already excluded from the review (Vinik 2014-1)
Vinik 2014-3	Vinik A, Sharma U, Feins K, Hsu C, Merante D. DS-5565 for the treatment of diabetic peripheral neuropathic pain: Randomized, double-blind, placebo-and active comparator-controlled phase ii study. Neurology Conference: 66th American Academy of Neurology Annual Meeting, AAN. 2014;82(10 SUPPL. 1).	Duplicate of study already excluded from the review (Vinik 2014-1)

Vinik 2014-4	Vinik AI, Sharma U, Feins K, Hsu C, Merante D. Safety/tolerability profile of DS-5565: A new potent, specific alpha2-delta ligand for the treatment of diabetic peripheral neuro pathic pain. Diabetes. 2014;Conference: 74th Scientific Sessions of the American Diabetes Association. San Francisco, CA United States. Conference Publication: (var.pagings). 63 (SUPPL. 1):A298.	Duplicate of study already excluded from the review (Vinik 2014-1)
Vinik 2014-5	Vinik AI, Sharma U, Feins K, Hsu C, Merante D. A randomized, double-blind, placebo- and active comparator (pregabalin)-controlled phase II study of DS-5565 for the treatment of diabetic peripheral neuropathic pain. Diabetes. 2014;Conference: 74th Scientific Sessions of the American Diabetes Association. San Francisco, CA United States. Conference Publication: (var.pagings). 63 (SUPPL. 1):A294.	Duplicate of study already excluded from the review (Vinik 2014-1)